A phase I, open-label, multiple dose study to assess the tolerability, pharmacokinetics and pharmacodynamics of ARRY-142886 given on a daily oral regime in subjects with advanced solid malignancies
Latest Information Update: 16 Oct 2020
At a glance
- Drugs Selumetinib (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Pharmacodynamics
- 08 Dec 2006 Status change
- 19 Sep 2005 New trial record.